Prediction of Immune-related Adverse Events Induced by Anti-CTLA4 and Anti-PD1/PDL1 Drugs by Means of a Battery of Autoantibodies. A Multicenter Prospective Observational Cohort Study
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- Acronyms AUTENTIC
Most Recent Events
- 01 Apr 2025 Status changed from recruiting to completed.
- 28 Feb 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2023.
- 28 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Oct 2023.